Showing results (421-430 of 446) with videos related to
Sort By:
Pageof 45
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.Transplantation and Cellular Therapy|June 13, 2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, et al.British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.Blood Advances|August 26, 2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agentsLindsey E Roeker, Peter Dreger, Jennifer R Brown, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2018
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing AssaysCatherine C Coombs, Nancy K Gillis, Xianming Tan, et al.Pageof 45